Heiko Hawlisch

This inventor holds 6 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Shire Orphan Therapies Gmbh, Alcon Research, Ltd., Shire Orphan Thereapies Gmbh. Active years: 2013-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heiko Hawlisch. Retrieved from https://idiyas.com/inventor/heiko-hawlisch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 33.3

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 11.0

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

4 out of 10

Shire Orphan Therapies Gmbh

Shire Orphan Thereapies Gmbh

patent

Years Active: 2013-2019

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10196423 - NPR-B agonists (2019-02-05),

2. 9982016 - NPR-B agonists (2018-05-29),

3. 9745344 - NPR-B agonists (2017-08-29),

4. 9458198 - Cyclic peptide-based NPR-B agonists (2016-10-04),

5. 9169293 - NPR-B agonists (2015-10-27),

6. 8546523 - NPR-B agonists (2013-10-01),

Title: The Innovative Journey of Heiko Hawlisch

Introduction

Heiko Hawlisch, an accomplished inventor based in Berlin, Germany, is known for his significant contributions to the field of pharmaceutical sciences. With a total of six patents to his name, his innovative work focuses on novel compounds that hold promise in therapeutic applications.

Latest Patents

Among his latest patents are the NPR-B agonists. These patents disclose novel compounds exhibiting NPR-B agonistic activity, which are primarily linear peptides consisting of 8 to 13 conventional or non-conventional L- or D-amino acid residues. These residues are uniquely connected through peptide bonds, showcasing Hawlisch's expertise in peptide chemistry.

Career Highlights

Throughout his career, Heiko has made notable advancements while working in esteemed organizations such as Shire Orphan Therapies GmbH and Alcon Research, Ltd. His innovative mindset and dedication to research have made a significant impact in the pharmaceutical industry.

Collaborations

Heiko has collaborated with remarkable professionals, including Frank Osterkamp and Gerd Hummel. These collaborations highlight not only his ability to work within teams but also the collective drive towards breakthroughs in the field of pharmacology.

Conclusion

Heiko Hawlisch's work exemplifies the spirit of innovation and dedication within the scientific community. By continuously advancing the understanding and applications of NPR-B agonists, he paves the way for future therapeutic possibilities that may benefit patients worldwide.

Profile summary based on public USPTO records.